112 related articles for article (PubMed ID: 28498805)
1. FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes.
Rinaldetti S; Wirtz RM; Worst TS; Eckstein M; Weiss CA; Breyer J; Otto W; Bolenz C; Hartmann A; Erben P
Oncotarget; 2017 Jul; 8(29):47595-47606. PubMed ID: 28498805
[TBL] [Abstract][Full Text] [Related]
2. CD19
Jiang Q; Fu Q; Chang Y; Liu Z; Zhang J; Xu L; Zhu Y; Wang Y; Zhang W; Xu J
Cancer Immunol Immunother; 2019 Jan; 68(1):45-56. PubMed ID: 30259082
[TBL] [Abstract][Full Text] [Related]
3. Subclassification, survival prediction and drug target analyses of chemotherapy-naïve muscle-invasive bladder cancer with a molecular screening.
Rinaldetti S; Rempel E; Worst TS; Eckstein M; Steidler A; Weiss CA; Bolenz C; Hartmann A; Erben P
Oncotarget; 2018 May; 9(40):25935-25945. PubMed ID: 29899832
[TBL] [Abstract][Full Text] [Related]
4. Exploration of genetics commonness between bladder cancer and breast cancer based on a silcio analysis on disease subtypes.
Xu W; Xia H; Liu W; Zheng W; Hua L
Technol Health Care; 2018; 26(S1):361-377. PubMed ID: 29758961
[TBL] [Abstract][Full Text] [Related]
5. Digital spatial profiling of the microenvironment of muscle invasive bladder cancer.
Eyers M; Irlam J; Marshall G; Smith V; Baker A; Frost L; Hoskin P; Choudhury A; West C
Commun Biol; 2024 Jun; 7(1):737. PubMed ID: 38890455
[TBL] [Abstract][Full Text] [Related]
6. Regarding the role of HER2 overexpression on the survival in muscle-invasive bladder cancer.
Yang W; Liu J
Int J Surg; 2024 Apr; 110(4):2466. PubMed ID: 38241347
[No Abstract] [Full Text] [Related]
7. Tetramethylpyrazine inhibits prostate cancer progression by downregulation of forkhead box M1.
Zhou Y; Ji Z; Yan W; Zhou Z; Li H; Xiao Y
Oncol Rep; 2017 Aug; 38(2):837-842. PubMed ID: 28677763
[TBL] [Abstract][Full Text] [Related]
8. FOXM1 in Cancer: Interactions and Vulnerabilities.
Gartel AL
Cancer Res; 2017 Jun; 77(12):3135-3139. PubMed ID: 28584182
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.
Robertson AG; Kim J; Al-Ahmadie H; Bellmunt J; Guo G; Cherniack AD; Hinoue T; Laird PW; Hoadley KA; Akbani R; Castro MAA; Gibb EA; Kanchi RS; Gordenin DA; Shukla SA; Sanchez-Vega F; Hansel DE; Czerniak BA; Reuter VE; Su X; de Sa Carvalho B; Chagas VS; Mungall KL; Sadeghi S; Pedamallu CS; Lu Y; Klimczak LJ; Zhang J; Choo C; Ojesina AI; Bullman S; Leraas KM; Lichtenberg TM; Wu CJ; Schultz N; Getz G; Meyerson M; Mills GB; McConkey DJ; ; Weinstein JN; Kwiatkowski DJ; Lerner SP
Cell; 2017 Oct; 171(3):540-556.e25. PubMed ID: 28988769
[TBL] [Abstract][Full Text] [Related]
10. Classification of bladder cancer cell lines according to regulon activity.
Eray A; Erkek-Özhan S
Turk J Biol; 2021; 45(6):656-666. PubMed ID: 35068946
[TBL] [Abstract][Full Text] [Related]
11. RNA Expression of DNA Damage Response Genes in Muscle-Invasive Bladder Cancer: Influence on Outcome and Response to Adjuvant Cisplatin-Based Chemotherapy.
Herrmann J; Schmidt H; Nitschke K; Weis CA; Nuhn P; von Hardenberg J; Michel MS; Erben P; Worst TS
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33919527
[TBL] [Abstract][Full Text] [Related]
12. Neuropilin-2 and Its Transcript Variants Correlate with Clinical Outcome in Bladder Cancer.
Förster S; Givehchi M; Nitschke K; Mayr T; Kilian K; Dutta S; Datta K; Nuhn P; Popovic Z; Muders MH; Erben P
Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918816
[TBL] [Abstract][Full Text] [Related]
13. Experimental and bioinformatics considerations in cancer application of single cell genomics.
Tan JHJ; Kong SL; Tai JA; Poh HM; Yao F; Sia YY; Lim EKH; Takano AM; Tan DS; Javed A; Hillmer AM
Comput Struct Biotechnol J; 2021; 19():343-354. PubMed ID: 33489004
[TBL] [Abstract][Full Text] [Related]
14. Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant Chemotherapy.
Taubert H; Eckstein M; Epple E; Jung R; Weigelt K; Lieb V; Sikic D; Stöhr R; Geppert C; Weyerer V; Bertz S; Kehlen A; Hartmann A; Wullich B; Wach S
Cells; 2021 Jan; 10(1):. PubMed ID: 33467469
[TBL] [Abstract][Full Text] [Related]
15.
Wu S; Nitschke K; Heinkele J; Weis CA; Worst TS; Eckstein M; Porubsky S; Erben P
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31766561
[No Abstract] [Full Text] [Related]
16. [Molecular tumor board-urothelial cancer].
Hupe MC; Gakis G; Seiler R
Urologe A; 2019 Jul; 58(7):760-767. PubMed ID: 31172245
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder.
Erben P; Sikic D; Wirtz RM; Martini T; Weis CA; Breyer J; Otto W; Keck B; Hartmann A; Bolenz C;
Virchows Arch; 2019 Feb; 474(2):209-217. PubMed ID: 30483954
[TBL] [Abstract][Full Text] [Related]
18. Emerging Biomarkers in Bladder Cancer Identified by Network Analysis of Transcriptomic Data.
Giulietti M; Occhipinti G; Righetti A; Bracci M; Conti A; Ruzzo A; Cerigioni E; Cacciamani T; Principato G; Piva F
Front Oncol; 2018; 8():450. PubMed ID: 30370253
[TBL] [Abstract][Full Text] [Related]
19. FOXM1 predicts disease progression in non-muscle invasive bladder cancer.
Rinaldetti S; Wirtz R; Worst TS; Hartmann A; Breyer J; Dyrskjot L; Erben P
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1701-1709. PubMed ID: 29959570
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
